Circulating von Willebrand factor antigen II in atherosclerosis: a comparison with von Willebrand factor and soluble thrombomodulin

被引:17
|
作者
Blann, AD [1 ]
de Romeuf, C
Mazurier, C
McCollum, CN
机构
[1] City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England
[2] LFB 59, R&D Dept, Lab Rech Hemostase, F-50911 Lille, France
[3] Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England
关键词
von Willebrand factor antigen II; von Willebrand factor; atherosclerosis;
D O I
10.1097/00001721-199804000-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand factor antigen II (vWFAgII) is the 100 kDa propolypeptide of endothelial cell marker von Willebrand factor (vWF). Our aim was to determine the relationship between vWFAgII and mature VWF and an additional endothelial cell marker, soluble thrombomodulin, in atherosclerosis. To do this, we measured levels of all three by enzyme-linked immunosorbent assay in plasma obtained from 24 patients with peripheral vascular disease (PVD), from 25 patients who survived a myocardial infarction [i.e. had ischaemic heart disease (IHD)], and from 47 age- and sex-matched controls. We found raised levels of vWFAgII in PVD (57.3 +/- 15.3 mu g/dl; mean +/- standard deviation) and in IHD (53.4 +/- 19.2 mu g/dl) compared with the controls (35.7 +/- 12.0 mu g/dl; analysis of variance P < 0.001). Raised levels of vWf were found in both groups of patients but raised soluble thrombomodulin was found only in patients with PVD. Levels of vWFAgII correlated with those of vWf (r = 0.45, P < 0.001) but not with soluble thrombomodulin (r = 0.14, P = 0.17), nor any of the major risk factors for atherosclerosis. Our brief study reports raised levels of vWFAgII in atherosclerosis. This may, like that of vWf, be related to endothelial cell damage, although the incomplete correlation between the two implies different metabolic and/or release mechanisms. Blood Coag Fibrinol 9:261-266 (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 50 条
  • [1] Characterization of von Willebrand factor antigen II in a therapeutic von Willebrand factor concentrate
    DeRomeuf, C
    Samor, B
    Mazurier, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1218 - 1218
  • [2] Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis
    Blann, AD
    Seigneur, M
    Adams, RA
    McCollum, CN
    [J]. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 1996, 12 (02) : 218 - 222
  • [3] Evidence that von Willebrand factor antigen II interacts with mature platelet and plasma von Willebrand factor
    deRomeuf, C
    Mazurier, C
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : P2630 - P2630
  • [4] VON-WILLEBRAND-FACTOR AND ATHEROSCLEROSIS
    BLANN, AD
    [J]. JOURNAL OF INTERNAL MEDICINE, 1995, 237 (04) : 432 - 433
  • [5] Von Willebrand factor deficiency and atherosclerosis
    van Galen, K. P. M.
    Tuinenburg, A.
    Smeets, E. M.
    Schutgens, R. E. G.
    [J]. BLOOD REVIEWS, 2012, 26 (05) : 189 - 196
  • [6] VON-WILLEBRAND-FACTOR AND ATHEROSCLEROSIS
    BLANN, AD
    [J]. CIRCULATION, 1993, 88 (04) : 1962 - 1962
  • [7] Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status
    Lee, Adrienne
    Sinclair, Gary
    Valentine, Karen
    James, Paula
    Poon, Man-Chiu
    [J]. BLOOD, 2014, 124 (05) : E1 - E3
  • [8] Comparison between von Willebrand factor (vWF) and vWF antigen II in normal individuals and patients with von Willebrand disease
    de Romeuf, C
    Mazurier, C
    [J]. THROMBOSIS AND HAEMOSTASIS, 1998, 80 (01) : 37 - 41
  • [9] von Willebrand disease and von Willebrand factor
    Sadler, Brooke
    Castaman, Giancarlo
    O'Donnell, James S.
    [J]. HAEMOPHILIA, 2022, 28 : 11 - 17
  • [10] von Willebrand Factor and von Willebrand Disease
    王兆钺
    [J]. 血栓与止血学, 2005, (04) : 147 - 149